206 related articles for article (PubMed ID: 1758446)
1. Lesion of the subthalamic nucleus for the alleviation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism in the primate.
Aziz TZ; Peggs D; Sambrook MA; Crossman AR
Mov Disord; 1991; 6(4):288-92. PubMed ID: 1758446
[TBL] [Abstract][Full Text] [Related]
2. Alleviation of experimental hemiparkinsonism by high-frequency stimulation of the subthalamic nucleus in primates: a comparison with L-Dopa treatment.
Benazzouz A; Boraud T; Féger J; Burbaud P; Bioulac B; Gross C
Mov Disord; 1996 Nov; 11(6):627-32. PubMed ID: 8914087
[TBL] [Abstract][Full Text] [Related]
3. The role of the subthalamic nucleus in the origin of hemiballism and parkinsonism: new surgical perspectives.
Guridi J; Obeso JA
Adv Neurol; 1997; 74():235-47. PubMed ID: 9348418
[No Abstract] [Full Text] [Related]
4. Fifteen months' follow-up on bilateral embryonic mesencephalic grafts in two cases of severe MPTP-induced parkinsonism.
Widner H; Tetrud J; Rehncrona S; Snow BJ; Brundin P; Björklund A; Lindvall O; Langston JW
Adv Neurol; 1993; 60():729-33. PubMed ID: 8420218
[No Abstract] [Full Text] [Related]
5. Subthalamic nucleotomy alleviates parkinsonism in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed primate.
Aziz TZ; Peggs D; Agarwal E; Sambrook MA; Crossman AR
Br J Neurosurg; 1992; 6(6):575-82. PubMed ID: 1361741
[TBL] [Abstract][Full Text] [Related]
6. Does increased excitatory drive from the subthalamic nucleus contribute to dopaminergic neuronal death in Parkinson's disease?
Luquin MR; Saldise L; Guillén J; Belzunegui S; San Sebastián W; Izal A; Garrido P; Vázquez M
Exp Neurol; 2006 Oct; 201(2):407-15. PubMed ID: 16806173
[TBL] [Abstract][Full Text] [Related]
7. The primate subthalamic nucleus. III. Changes in motor behavior and neuronal activity in the internal pallidum induced by subthalamic inactivation in the MPTP model of parkinsonism.
Wichmann T; Bergman H; DeLong MR
J Neurophysiol; 1994 Aug; 72(2):521-30. PubMed ID: 7983516
[TBL] [Abstract][Full Text] [Related]
8. Alleviation of parkinsonism by antagonism of excitatory amino acid transmission in the medial segment of the globus pallidus in rat and primate.
Brotchie JM; Mitchell IJ; Sambrook MA; Crossman AR
Mov Disord; 1991; 6(2):133-8. PubMed ID: 1647492
[TBL] [Abstract][Full Text] [Related]
9. The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease.
Jenner P; Marsden CD
J Neural Transm Suppl; 1986; 20():11-39. PubMed ID: 3091760
[TBL] [Abstract][Full Text] [Related]
10. Subthalamotomy improves MPTP-induced parkinsonism in monkeys.
Guridi J; Herrero MT; Luquin R; Guillen J; Obeso JA
Stereotact Funct Neurosurg; 1994; 62(1-4):98-102. PubMed ID: 7631095
[TBL] [Abstract][Full Text] [Related]
11. Involvement of the subthalamic nucleus in glutamatergic compensatory mechanisms.
Bezard E; Boraud T; Bioulac B; Gross CE
Eur J Neurosci; 1999 Jun; 11(6):2167-70. PubMed ID: 10336685
[TBL] [Abstract][Full Text] [Related]
12. The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism.
Bergman H; Wichmann T; Karmon B; DeLong MR
J Neurophysiol; 1994 Aug; 72(2):507-20. PubMed ID: 7983515
[TBL] [Abstract][Full Text] [Related]
13. Pathophysiology of parkinsonian motor abnormalities.
Wichmann T; DeLong MR
Adv Neurol; 1993; 60():53-61. PubMed ID: 8420185
[No Abstract] [Full Text] [Related]
14. [MPTP and Parkinson's disease].
Imai H
No To Shinkei; 1988 Nov; 40(11):1011-24. PubMed ID: 3064783
[No Abstract] [Full Text] [Related]
15. [A mouse model of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced parkinsonism: effect of norepinephrine terminal destruction].
Nishi K; Kondo T; Narabayashi H
No To Shinkei; 1987 Jul; 39(7):663-72. PubMed ID: 3314916
[TBL] [Abstract][Full Text] [Related]
16. Chronic exposure to MPTP as a primate model of progressive parkinsonism: a pilot study with a free radical scavenger.
Blanchet PJ; Konitsiotis S; Hyland K; Arnold LA; Pettigrew KD; Chase TN
Exp Neurol; 1998 Oct; 153(2):214-22. PubMed ID: 9784281
[TBL] [Abstract][Full Text] [Related]
17. Bilateral akinesia in drug-induced parkinsonism after a subthalamic lesion.
Kulisevsky J; Lima de Freitas M; Barraquer-Bordas L
Mov Disord; 1994 Jan; 9(1):111-2. PubMed ID: 8139592
[No Abstract] [Full Text] [Related]
18. Dyskinesia and wearing-off following dopamine D1 agonist treatment in drug-naive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates.
Blanchet PJ; Grondin R; Bédard PJ
Mov Disord; 1996 Jan; 11(1):91-4. PubMed ID: 8771074
[TBL] [Abstract][Full Text] [Related]
19. [Clinical and biochemical parameters of parkinsonism induced by 1-methyl-4-phenyl-1,2,2,6-tetrahydropyridine and its methyl-phenyl and methoxy-phenyl derivatives in C57Bl/6 mice].
Lermontova NN; Soliakov LS; Bachurin SO; Serkova TP; Petrova LN; Dranyĭ OA; Tkachenko SE; Kalashnikov VV
Biull Eksp Biol Med; 1990 Oct; 110(10):397-9. PubMed ID: 2279092
[TBL] [Abstract][Full Text] [Related]
20. The primate subthalamic nucleus. I. Functional properties in intact animals.
Wichmann T; Bergman H; DeLong MR
J Neurophysiol; 1994 Aug; 72(2):494-506. PubMed ID: 7983514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
